Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting

On April 21, 2026 Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, reported all submitted abstracts have been selected for oral presentations at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, to be held from May 29-June 2, 2026, in Chicago, Illinois, USA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The four oral presentations will include:

Phase 1b clinical data on anzu-cel, the Company’s lead PRAME cell therapy, in advanced cutaneous and uveal melanoma with a focus on characterizing response dynamics
Updated Phase 1a dose-escalation and Phase 1b dose-expansion data for the second-generation (GEN2) PRAME cell therapy candidate, IMA203CD8, in gynecologic cancers at clinically relevant dose levels, which could support its development toward a tumor-agnostic approach
Updated Phase 1 data on PRAME cell therapies in synovial sarcoma, further demonstrating the potential to address diverse tumor types beyond melanoma and gynecologic cancers
Updated results for the MAGEA4/8 bispecific, IMA401, across multiple cancers, highlighting its potential as part of a combination approach with the Company’s PRAME bispecific, IMA402, aimed at synergistic activity and expanded patient reach
Together, these data underscore the continued advancement of Immatics’ PRAME franchise and its focus on developing novel immunotherapies for patients with solid tumors.

Full abstracts will be available on the ASCO (Free ASCO Whitepaper) website on May 21, 2026, at 5:00 pm ET.

Details on Oral Presentations

PRAME Cell Therapies: Anzu-cel (IMA203) and IMA203CD8 (GEN2)
Title: Patient-level clinical response dynamics in advanced melanoma with anzutresgene autoleucel (anzu-cel), a PRAME-directed T-cell receptor (TCR) T-cell therapy
Presenting author: Davar Diwakar, MD
Session: Oral Abstract Session – Melanoma/Skin Cancers
Date / Time: June 1, 2026 / 8:00 – 11:00 am CDT
Abstract ID: 9508

Title: Phase 1a study results for IMA203CD8, a PRAME-directed T-cell receptor (TCR) T-cell therapy, in ovarian cancer
Presenting author: Antonia Busse, MD
Session: Rapid Oral Abstract Session – Gynecologic Cancer
Date / Time: May 30, 2026 / 8:00 – 9:30 am CDT
Abstract ID: 5509

Title: Phase 1 study results with PRAME-directed T-cell receptor (TCR) T-cell therapies in synovial sarcoma
Presenting author: Dejka M. Araujo, MD
Session: Rapid Oral Abstract Session – Sarcoma
Date / Time: May 31, 2026 / 4:30 – 6:00 pm CDT
Abstract ID: 11516

MAGEA4/8 Bispecific: IMA401
Title: First-in-human results with IMA401, a MAGEA4/8 targeted T-cell receptor-based bispecific T-cell engager (TCER), in recurrent or refractory solid tumors
Presenting author: Martin Wermke, MD
Session: Developmental Therapeutics – Immunotherapy
Date / Time: May 31, 2026 / 8:00 – 11:00 am CDT
Abstract ID: 2507

(Press release, Immatics, APR 21, 2026, View Source [SID1234664611])